- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT03588975
Badanie MACI u pacjentów w wieku od 10 do 17 lat z objawowymi wadami chrzęstnymi lub kostno-chrzęstnymi stawu kolanowego (PEAK)
Prospektywne, otwarte, randomizowane, równoczesne, podłużne, wieloośrodkowe badanie kliniczne fazy 3 z kontrolą aktywną bezpieczeństwa i skuteczności produktu leczniczego MACI u pacjentów w wieku od 10 do 17 lat z objawowymi wadami chrzęstnymi lub kostno-chrzęstnymi stawu kolanowego spowodowanymi zapaleniem kości i chrząstek Dissecans lub Ostra trauma
The objective of this study is to compare the efficacy and safety of MACI® vs arthroscopic microfracture in the treatment of participants aged 10 to 17 years with symptomatic articular chondral or osteochondral defects of the knee.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
This is a 2-year prospective, multicenter, randomized, open-label, parallel group clinical trial; a total of 45 participants, ages 10 to 17 years, will be randomized to receive a 1-time treatment with MACI or microfracture (2:1, 30 MACI:15 microfracture).
After meeting screening criteria at the initial visit, all participants will have a screening arthroscopy to further assess study eligibility. During the screening arthroscopy, participants will be further evaluated against entry criteria. Cartilage lesion size will be measured prior to any cartilage repair procedure and randomization. All participants who meet the eligibility criteria and are considered suitable for treatment in the study will have a cartilage biopsy taken prior to randomization to study treatment. Eligible participants will be randomized during the screening arthroscopy procedure to receive either MACI or microfracture treatment. Participants randomized to microfracture will undergo the procedure during the screening arthroscopy.
All biopsied tissue will be sent to the Vericel manufacturing facility in Massachusetts, where the sample will be processed to isolate the autologous chondrocytes. Cells from participants randomized to the MACI group will be used in the preparation of the MACI implant; cells from participants randomized to the microfracture group will be cryopreserved.
Participants randomized to treatment with MACI will return within 12 weeks of the screening arthroscopy to undergo the chondrocyte implantation procedure via arthrotomy. Participants are to follow a recommended postoperative rehabilitation program and compliance with the rehabilitation schedule will be monitored.
Participants will be followed post-study treatment for 2 years (104 Weeks).
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 3
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Vericel Clinical Affairs
- Numer telefonu: 978-347-2876
- E-mail: clinicalhotline@vcel.com
Lokalizacje studiów
-
-
California
-
Palo Alto, California, Stany Zjednoczone, 94304
- Rekrutacyjny
- Stanford University School of Medicine
-
Kontakt:
- Amishi Jobanputra
- Numer telefonu: 650-498-4180
- E-mail: amishij@stanford.edu
-
Główny śledczy:
- Kevin Shea
-
Sacramento, California, Stany Zjednoczone, 95817
- Rekrutacyjny
- Shriners Hospital for Children Northern California
-
Główny śledczy:
- Brian Haus
-
Kontakt:
- Kory Bettencourt
- Numer telefonu: 916-453-5030,
- E-mail: kbettencourt@shrinenet.org
-
Sacramento, California, Stany Zjednoczone, 95817
- Rekrutacyjny
- University of California Davis Lawrence J. Ellison Ambulatory Care Center Orthopaedic Surgery
-
Główny śledczy:
- Brian Haus
-
Kontakt:
- Julia Martin
- Numer telefonu: 916-734-8175
- E-mail: jyhmartin@health.ucdavis.edu
-
-
Louisiana
-
New Orleans, Louisiana, Stany Zjednoczone, 70121
- Rekrutacyjny
- Ochsner Health System-Elmwood
-
Kontakt:
- Joseph Laurent
- Numer telefonu: 504-842-0263
- E-mail: Joseph.laurent@ochsner.org
-
Główny śledczy:
- Brian Godshaw
-
-
Maryland
-
Baltimore, Maryland, Stany Zjednoczone, 21224
- Rekrutacyjny
- Johns Hopkins Hospital
-
Kontakt:
- Rushyuan Jay Lee, MD
- Numer telefonu: 443-997-2663
- E-mail: rlee74@jhmi.edu
-
Kontakt:
- Gabrielle Reichard
- Numer telefonu: 410-502-3626
- E-mail: greicha1@jhmi.edu
-
Główny śledczy:
- Rushyuan Jay Lee
-
-
Michigan
-
Ann Arbor, Michigan, Stany Zjednoczone, 48106
- Rekrutacyjny
- University of Michigan Medsport Orthopaedic Surgery
-
Kontakt:
- Christopher Ray
- Numer telefonu: 734-615-0934
- E-mail: raychri@med.umich.edu
-
Główny śledczy:
- Eileen Crawford
-
-
New York
-
The Bronx, New York, Stany Zjednoczone, 10467
- Zakończony
- Montefiore Medical Center/Albert Einstein College of Medicine
-
-
Ohio
-
Akron, Ohio, Stany Zjednoczone, 44308
- Rekrutacyjny
- Akron Children's Hospital
-
Kontakt:
- John Polousky, MD
- Numer telefonu: 330-543-3500
- E-mail: JPolousky@akronchildrens.org
-
Główny śledczy:
- John Polousky
-
Columbus, Ohio, Stany Zjednoczone, 43202
- Rekrutacyjny
- The Ohio State University Jameson Crane Sports Medicine Institute
-
Kontakt:
- Jenna DeFranco
- Numer telefonu: 614-293-2761
- E-mail: jenna.defranco@osumc.edu
-
Główny śledczy:
- Christopher Kaeding
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19104
- Rekrutacyjny
- Penn Medicine University City
-
Kontakt:
- Dorothy Brill
- Numer telefonu: 215-273-5062
- E-mail: dcbrill@upenn.edu
-
Główny śledczy:
- James Carey
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19104
- Rekrutacyjny
- The Children's Hospital of Philadelphia - The Hub for Clinical Collaboration
-
Kontakt:
- Divya Talwar
- Numer telefonu: 215-590-1527
- E-mail: talward@chop.edu
-
Główny śledczy:
- Theodore Ganley
-
-
Rhode Island
-
East Providence, Rhode Island, Stany Zjednoczone, 02914
- Rekrutacyjny
- University Orthopedics, Inc.
-
Kontakt:
- Cyndi Chrostek
- Numer telefonu: 401-318-0529
- E-mail: cchrostek@brownhealth.org
-
Główny śledczy:
- Nicholas Lemme
-
-
Texas
-
Houston, Texas, Stany Zjednoczone, 77094
- Zakończony
- Texas' Children Hospital
-
Plano, Texas, Stany Zjednoczone, 75024
- Zakończony
- Children's Medical Center Plano
-
-
Wisconsin
-
Milwaukee, Wisconsin, Stany Zjednoczone, 53201
- Rekrutacyjny
- Children's Hospital of Wisconsin
-
Kontakt:
- John Erickson, DO
- Numer telefonu: 414-337-7325
- E-mail: JErickson2@childrenswi.org
-
Główny śledczy:
- John Erickson
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
-
Age 10 to 17 years at the time of planned randomization
-
Symptomatic cartilage or osteochondral defects
-
One or more International Cartilage Repair Society (ICRS) Grade III or IV chondral or unsalvageable osteochondral defects located on the femoral condyles and/or trochlea amenable to treatment with the surgical procedure determined at randomization (MACI or microfracture).
- Concurrent ICRS Grade I and II defects are acceptable on the tibia if they remain untreated (or are treated with debridement only) at the time of study treatment.
- Participants with a potentially re-attachable osteochondral fragment, identified by magnetic resonance imaging (MRI) and that has not previously been repaired, may be consented to the study and undergo baseline assessments per protocol and prior to confirmatory arthroscopy (Visit 2). At arthroscopy, an attempt will be made to reattach the osteochondral fragment. If this is successful, the participant will be excluded from the study and deemed an intra-operative screen failure. If the attempted reattachment fails and no other exclusion criteria apply, the participant may continue in the PEAK study: a MACI biopsy will be taken, the participant will be randomized and treated per protocol.
-
At least 1 defect size ≥1.5 cm2 on the patella, femoral condyles and/or the trochlea; defects include OCD lesions with a bone lesion depth of ≤6 mm and does not require a bone graft.
-
Salvageable OCD lesions must have failed prior conservative and a reparative treatment, and the participant still experiences pain associated with the osteochondral lesion. Participants with defects as a result of trauma or unknown etiology are eligible regardless of prior treatments.
-
Stable target knee (i.e., anterior and posterior cruciate ligaments should be free of laxity as well as stable and intact). Ligament repair or reconstruction procedures are allowed prior to screening arthroscopy.
-
Intact meniscus or partial meniscus (at least 50% of functional meniscus remaining) in the target knee. Meniscal repair or resection might be performed either staged or concurrent with the cartilage repair procedure provided that the surgeon was able to confirm that at least 50% of functional meniscus would remain after the corrective meniscal treatment.
-
Written informed consent
Exclusion Criteria:
-
Any surgery on the target knee joint within 6 months prior to Screening (not including diagnostic arthroscopy)
-
Previous investigational drug or device use within 3 months prior to Screening
-
Avascular necrosis of the target knee (other than potential OCD lesion to be treated)
-
Participants with uninvolved open growth plates where the surgery necessitates crossing the growth plate, or where the depth of the lesion crosses the growth plate
-
ICRS Grade III or IV chondral or unsalvageable osteochondral defects located on the tibia or any lesion that is bipolar to the index lesion
-
Malalignment requiring concurrent osteotomy to correct tibial-femoral or patella-femoral alignment (prior guided growth treatment is not exclusionary)
-
Symptomatic musculoskeletal conditions in the lower limbs that could impede measurement of efficacy for the target knee joint
-
Concomitant inflammatory disease or other conditions that affects the joints (eg, rheumatoid arthritis, metabolic bone disease, psoriasis, symptomatic chondrocalcinosis)
-
Known history of septic arthritis in the index knee joint
-
Current malignancy or treatment for malignancy within the past 5 years
-
Known history of hypersensitivity to gentamicin, other aminoglycosides, or products of porcine or bovine origin
-
Females who are pregnant or lactating
-
Participants who, in the opinion of the Investigator, have significant medical or psychosocial problems that warrant exclusion. Examples of significant problems included but are not limited to:
- Any condition that has potential for negatively impacting intra or postoperative course
- Conditions that limit compliance with rehabilitation program
- Any condition that has potential for significantly limiting participant's ability to assess postoperative knee function
- Any condition, psychiatric or otherwise, that would preclude informed consent/assent, consistent follow-up, or compliance with any aspect of the study
- Participant is currently abusing drugs or alcohol or, in the opinion of the Investigator, at high risk for poor compliance
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: MACI
autologous cultured chondrocytes on porcine collagen membrane |
autologous cultured chondrocytes on porcine collagen membrane |
|
Inny: microfracture
surgical procedure |
Arthroscopic microfracture treatment |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Proportion of Participants Who Achieve ≥ 10-point Improvement From Baseline in KOOS-Child Pain and Function (Sports and Recreational Activities) Subscale Scores
Ramy czasowe: Baseline and Week 104
|
A responder is defined as a participant with ≥ 10-point change (improvement) in both the KOOS-Child Pain and Function (Sports and Recreational activities) scores from Baseline scores. The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the participant's opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL). |
Baseline and Week 104
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change from Baseline in KOOS-Child subscores
Ramy czasowe: Baseline and Week 104
|
The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the participant's opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL). |
Baseline and Week 104
|
|
Change from Baseline in KOOS-Child subscores
Ramy czasowe: Baseline and Week 52
|
The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the participant's opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL). |
Baseline and Week 52
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Treatment Emergent Adverse Events
Ramy czasowe: Week 104
|
A treatment emergent untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. |
Week 104
|
Współpracownicy i badacze
Sponsor
Śledczy
- Dyrektor Studium: Jonathan Hopper, BSc (Hons), MB ChB, FRCSEd, Vericel Corporation
Publikacje i pomocne linki
Przydatne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 55-1702-1
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .